Opendata, web and dolomites

LDC4PCaTher

BMX-targeted ligand-drug conjugates for prostate cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LDC4PCaTher project word cloud

Explore the words cloud of the LDC4PCaTher project. It provides you a very rough idea of what is the project "LDC4PCaTher" about.

conjugates    therapy    ratio    drugs    strategies    avenues    blood    producing    weight    index    risk    cytokines    significantly    regulated    minimal    ligands    immunogenic    antibody    tumours    chromosome    payload    malignant    interferes    treatments    inflammatory    adme    release    ldcs    cancers    antibodies    radiation    systematically    accumulate    alternative    tumour    limited    site    safe    applicable    damage    easier    bone    cells    cancer    chemically    cytotoxic    prostate    building    patient    marrow    therapeutic    ligand    penetration    substances    toxicities    tuning    vehicles    care    bmx    dependent    severe    date    standard    chemical    tyrosine    markedly    drug    monoclonal    time    radionuclides    overexpressing    disease    fine    chemotherapy    pro    tissue    whilst    benefit    selectively    negligible    agents    superior    injection    treatment    kinase    healthy    performance    explore    modify    conjugated    maximizing    profile    molecular    efficacy    heavily    relies    ldc   

Project "LDC4PCaTher" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 160˙635 €
 EC max contribution 160˙635 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2019-01-12

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 160˙635.00

Map

 Project objective

Standard of care strategies for the treatment of cancer still relies heavily on non-specific radiation and chemotherapy. These treatments are commonly associated with severe toxicities and in many cases only offer limited benefit for the patient. The targeted delivery of radionuclides, cytotoxic drugs and pro-inflammatory cytokines into malignant tissue, on the other hand, can markedly improve the therapeutic index and overall efficacy of such substances. Whilst monoclonal antibodies are the most widely used delivery vehicles to date, low molecular weight targeted agents are emerging as a promising alternative to antibody-based drug delivery. These ligands have negligible immunogenic risk and are easier to chemically modify enabling fine tuning of their ADME profile. As a result, it is possible to achieve a time dependent release of the cytotoxic payload at the target tissue maximizing its therapeutic efficacy while producing minimal damage to healthy cells. Most importantly, depth of tumour penetration and tumour-to-blood distribution ratio after injection should be significantly superior. We therefore propose to systematically investigate the targeting performance of bone marrow tyrosine kinase in chromosome X (BMX) ligands for the targeted delivery of cytotoxic drugs into BMX-overexpressing tumours, namely prostate cancer. This project aims at (1) demonstrate that a BMX ligand can selectively accumulate in BMX-overexpressing cancers; (2) developing a general chemical approach for building safe ligand-drug conjugates (LDCs); and (3) when site-specifically conjugated to cytotoxic drug, this novel LDC is highly effective for the treatment of prostate cancer. This project is expected to explore new avenues for drug delivery systems since the concepts here proposed go beyond prostate cancer therapy as they can be applicable to any ligand that interferes with up-regulated disease-related pathways.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LDC4PCATHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LDC4PCATHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NeoPur (2019)

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Read More  

DiMaS (2019)

Retrospective genomic analyses of shortfin Mako shark (Isurus oxyrinchus) using DNA from archived jaws

Read More  

FOCUSIS (2020)

Focal volume Control Using Structured Illumination Sources

Read More